MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)

Kater, A. P., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., Serna, J. d. l., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Thadani‐Mulero, M., Lefebure, M., Jiang, Y., Millen, R., Boyer, M., & Seymour, J. F. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology, 41(S2), 239–242. Portico. https://doi.org/10.1002/hon.3163_156
Authors:
Arnon P. Kater
Rosemary Harrup
Thomas J. Kipps
Barbara Eichhorst
Carolyn Owen
Sarit Assouline
Nicole Lamanna
Tadeusz Robak
Javier de la Serna
Ulrich Jaeger
Guillaume Cartron
Marco Montillo
Clemens Mellink
Brenda Chyla
Maria Thadani-Mulero
Marcus Lefebure
Yanwen Jiang
Rosemary Millen
Michelle Boyer
John F. Seymour
Affiliated Authors:
Nicole Lamanna
Columbia Affiliation:
Subjects:
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1002/hon.3163_156
DOI:
10.1002/hon.3163_156
Journal:
Hematological Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: